Oxford Biomedica PLC Repayment of Debt Facility (7435D)

TIDMOXB

RNS Number : 7435D

Oxford Biomedica PLC

28 June 2019

Oxford Biomedica

Repayment of Debt Facility

Oxford, UK - 28 June 2019: Oxford Biomedica plc (LSE:OXB) ("OXB" or "the Group"), a leading gene and cell therapy group, announces that, further to the announcement of 28 May in relation to Novo Holdings' strategic investment in the Group and, in accordance with the stated use of proceeds from the transaction, Oxford Biomedica has now repaid in full its debt facility with Oaktree Capital Management.

-Ends-

 
 Enquiries: 
  Oxford Biomedica plc 
   John Dawson, Chief Executive Officer 
   Stuart Paynter, Chief Financial Officer 
   Catherine Isted, Head of Corporate          T: +44 (0)1865 783 000 
   Development & IR                            T: +44 (0)1865 783 000 
   Sarah MacLeod, Head of Communications       T: +44 (0)1865 954 161 / E: ir@oxb.com 
                                               T: +44 (0)7747 602 739 / E: media@oxb.com 
                                              T: +44 (0)20 3709 5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew Neal

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCDDGDLLDDBGCR

(END) Dow Jones Newswires

June 28, 2019 02:01 ET (06:01 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024